Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

The stock's fall snapped a four-day winning streak.

For Pfizer, the consensus sales estimate for the current quarter of $17.5 billion indicates a year-over-year change of +22.8%. For the current and next fiscal years, $63.36 billion and $62.98 ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

But I actually see this as a risk factor since according to my earlier analysis, Pfizer ... company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is ...

Diving into Analyst Ratings: An In-Depth Exploration The analysis of recent analyst ... Revenue Growth: Over the 3M period, Pfizer showcased positive performance, achieving a revenue growth ...

Pfizer’s PFE $13.7 billion in revenue (an ... Management said that full-year performance is trending toward the high end of EPS guidance. Cardiomyopathy drugs including Vyndaqel grew 31% ...

Last year was a strong one in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to a decline in revenues and profits. It saw improved performance of its ...

Shares of Pfizer jumped by as much as 11 percent to Rs 4,995 apiece on May 20 after the company posted a strong performance for the March quarter (Q4FY25). In the past month, this pharma stock ...